Abstract
Multifunctional mitochondrial enzyme 17β-hydroxysteroid dehydrogenase type 10 plays a role in the development of Alzheimer’s disease. However, changes in its expression in the brain or cerebrospinal fluid are not fully specific for this type of dementia. Our previous study revealed that complexes of the enzyme and amyloid β in cerebrospinal fluid could serve as a more specific biomarker of Alzheimer’s disease than either the enzyme or amyloid β individually when compared to autoimmune multiple sclerosis. In this study, enzyme-linked immunosorbent assay and the surface plasmon resonance biosensor method were used to analyse cerebrospinal fluid of patients with various neuroinflammatory diseases. Significant differences in the levels of the total enzyme, complexes, amyloid β 1-42 and total τ/phospho-τ were found in Alzheimer’s disease patients while differences in complexes, total amyloid β and amyloid β 1- 42 were observed in patients with neuroinflammatory diseases (except for multiple sclerosis) when compared to nonneuroinflammatory controls. The interactions of the enzyme with amyloid β appeared to depend strongly on neuroinflammation-sensitive amyloid β. Our data demonstrated that oligomerisation/aggregation of intracellular amyloid β peptides was important in Alzheimer’s disease while extracellular amyloid β could play a role in neuroinflammatory diseases. Phospho-τ is currently the best biomarker of Alzheimer’s disease.
Keywords: Amyloid β, mitochondrial enzyme, Alzheimer’s disease, neuroinflammation
Current Alzheimer Research
Title:Neuroinflammation and Complexes of 17β -Hydroxysteroid Dehydrogenase type 10 - Amyloid β in Alzheimer's Disease
Volume: 10 Issue: 2
Author(s): Zdena Kristofikova, Daniela Ripova, Ales Bartos, Marketa Bockova, Katerina Hegnerova, Jan Ricny, Linda Cechova, Monika Vrajova and Jiri Homola
Affiliation:
Keywords: Amyloid β, mitochondrial enzyme, Alzheimer’s disease, neuroinflammation
Abstract: Multifunctional mitochondrial enzyme 17β-hydroxysteroid dehydrogenase type 10 plays a role in the development of Alzheimer’s disease. However, changes in its expression in the brain or cerebrospinal fluid are not fully specific for this type of dementia. Our previous study revealed that complexes of the enzyme and amyloid β in cerebrospinal fluid could serve as a more specific biomarker of Alzheimer’s disease than either the enzyme or amyloid β individually when compared to autoimmune multiple sclerosis. In this study, enzyme-linked immunosorbent assay and the surface plasmon resonance biosensor method were used to analyse cerebrospinal fluid of patients with various neuroinflammatory diseases. Significant differences in the levels of the total enzyme, complexes, amyloid β 1-42 and total τ/phospho-τ were found in Alzheimer’s disease patients while differences in complexes, total amyloid β and amyloid β 1- 42 were observed in patients with neuroinflammatory diseases (except for multiple sclerosis) when compared to nonneuroinflammatory controls. The interactions of the enzyme with amyloid β appeared to depend strongly on neuroinflammation-sensitive amyloid β. Our data demonstrated that oligomerisation/aggregation of intracellular amyloid β peptides was important in Alzheimer’s disease while extracellular amyloid β could play a role in neuroinflammatory diseases. Phospho-τ is currently the best biomarker of Alzheimer’s disease.
Export Options
About this article
Cite this article as:
Kristofikova Zdena, Ripova Daniela, Bartos Ales, Bockova Marketa, Hegnerova Katerina, Ricny Jan, Cechova Linda, Vrajova Monika and Homola Jiri, Neuroinflammation and Complexes of 17β -Hydroxysteroid Dehydrogenase type 10 - Amyloid β in Alzheimer's Disease, Current Alzheimer Research 2013; 10 (2) . https://dx.doi.org/10.2174/1567205011310020006
DOI https://dx.doi.org/10.2174/1567205011310020006 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Effects of Prostaglandin E-1 in Patients with Intermittent Claudication
Cardiovascular & Hematological Disorders-Drug Targets Role of APP and Aβ in Synaptic Physiology
Current Alzheimer Research APP Transgenic Mouse Models and their Use in Drug Discovery to Evaluate Amyloid-β Lowering Therapeutics
CNS & Neurological Disorders - Drug Targets Synaptic Dysfunction in Synucleinopathies
CNS & Neurological Disorders - Drug Targets A Hydrazide Linker Strategy for Heterobivalent Compounds as Ortho- and Allosteric Ligands of Acetylcholine-Binding Proteins
Current Topics in Medicinal Chemistry Current Therapeutic Strategies and Future Perspectives for the Prevention of Arterial Thromboembolism: Focus on Atrial Fibrillation
Current Pharmaceutical Design HIV-1 Tat Protein Exposure Potentiates Ethanol Reward and Reinstates Extinguished Ethanol-Conditioned Place Preference
Current HIV Research Antiplatelet Treatment in Peripheral Arterial Disease: The Role of Novel Antiplatelet Agents
Current Pharmaceutical Design Phosphodiesterase Inhibitors as Potential Cognition Enhancing Agents
Current Topics in Medicinal Chemistry Neurobiology of Bipolar Disorder: Abnormalities on Cognitive and Cortical Functioning and Biomarker Levels
CNS & Neurological Disorders - Drug Targets Oxidative Stress Correlates (OSC) in Diabetes Mellitus Patients
Current Diabetes Reviews Origin and Evolution of China Pharmacopoeia and Its Implication for Traditional Medicines
Mini-Reviews in Medicinal Chemistry Gene Therapy for Dentin Regeneration with Bone Morphogenetic Proteins
Current Gene Therapy Start Small and Stay Small: Minimizing Attrition in the Clinic with a Focus on CNS Therapeutics
Current Topics in Medicinal Chemistry Blood-Brain Barrier Changes in High Altitude
CNS & Neurological Disorders - Drug Targets PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism
Current Drug Targets Platelets: Their Potential Contribution to the Generation of Beta-amyloid Plaques in Alzheimer’s Disease
Current Neurovascular Research Metabolomic-Driven Elucidation of Serum Disturbances Associated with Alzheimer's Disease and Mild Cognitive Impairment
Current Alzheimer Research Effect of Nanotechnology Approaches on Anti-retroviral Molecule: Efavirenz
Current Organic Chemistry Understanding the Obstacles to Uptake of Intervention Programmes and Services for Persons with Dementia
Current Alzheimer Research